{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:52:26Z","timestamp":1792479146087,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32A009515"],"award-info":[{"award-number":["T32A009515"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clgc.2024.102284","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T11:39:38Z","timestamp":1733139578000},"page":"102284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2\/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6351-3300","authenticated-orcid":false,"given":"Rafee","family":"Talukder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-7507","authenticated-orcid":false,"given":"Dimitra Rafailia","family":"Bakaloudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3258-2984","authenticated-orcid":false,"given":"Dimitrios","family":"Makrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas N.","family":"Diamantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6353-3766","authenticated-orcid":false,"given":"Thomas","family":"Enright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5810-043X","authenticated-orcid":false,"given":"Jacob B.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-4954","authenticated-orcid":false,"given":"Ruben","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishita","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-7555","authenticated-orcid":false,"given":"Jason R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-2626","authenticated-orcid":false,"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Rey-C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai","family":"Alva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roubini","family":"Zakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5996-7262","authenticated-orcid":false,"given":"Aristotelis","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7398-0685","authenticated-orcid":false,"given":"Rafael Morales","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-1440","authenticated-orcid":false,"given":"David","family":"Marmolejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-5466","authenticated-orcid":false,"given":"James","family":"Korolewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Alonso","family":"Buznego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6526-9615","authenticated-orcid":false,"given":"Clara Castro","family":"Carballeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-8668","authenticated-orcid":false,"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-4426","authenticated-orcid":false,"given":"Ali Raza","family":"Khaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.clgc.2024.102284_bib0001","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clgc.2024.102284_bib0002","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2024.102284_bib0003","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102284_sbref0004","series-title":"Pembrolizumab (Keytruda): Advanced or Metastatic Urothelial Carcinoma","year":"2019"},{"key":"10.1016\/j.clgc.2024.102284_sbref0005","series-title":"Nivolumab for Treatment of Urothelial Carcinoma","year":"2019"},{"key":"10.1016\/j.clgc.2024.102284_sbref0006","series-title":"FDA Grants Accelerated Approval to Avelumab for Urothelial Carcinoma","year":"2019"},{"key":"10.1016\/j.clgc.2024.102284_sbref0007","series-title":"FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv With Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma","year":"2023"},{"issue":"1","key":"10.1016\/j.clgc.2024.102284_bib0008","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.102284_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.499","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102284_bib0010","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Thomas","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102284_sbref0011","series-title":"FDA Approves Enfortumab Vedotin-ejfv With Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer","year":"2023"},{"issue":"19","key":"10.1016\/j.clgc.2024.102284_bib0012","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine\u2013Cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden Michiel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102284_bib0013","unstructured":"Research C for DE and. FDA Approves Nivolumab in Combination With Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma. FDA. 2024 Mar 7 [cited 2024 Jun 7]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-combination-cisplatin-and-gemcitabine-unresectable-or-metastatic-urothelial."},{"issue":"12","key":"10.1016\/j.clgc.2024.102284_bib0014","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.102284_bib0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.432","article-title":"First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): a phase 3, randomized, double-blind study","volume":"40","author":"Loriot","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.102284_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.434","volume":"39","author":"Galsky","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102284_bib0017","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102284_bib0018","doi-asserted-by":"crossref","first-page":"viii327","DOI":"10.1093\/annonc\/mdy283.129","article-title":"Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M\/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): the phase III THOR study","volume":"29","author":"Loriot","year":"2018","journal-title":"Ann Oncol"},{"issue":"17_suppl","key":"10.1016\/j.clgc.2024.102284_bib0019","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4619","article-title":"Phase 3 THOR study: results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)","volume":"41","author":"Loriot","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102284_sbref0020","series-title":"FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma","year":"2019"},{"issue":"1","key":"10.1016\/j.clgc.2024.102284_bib0021","first-page":"326","article-title":"Clinical features of patients with MTAP-deleted bladder cancer","volume":"13","author":"De Souza","year":"2023","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clgc.2024.102284_bib0022","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41467-022-29397-z","article-title":"MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers","volume":"13","author":"Alhalabi","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.clgc.2024.102284_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/BLC-180196","article-title":"Systematic review: targeting HER2 in bladder cancer","volume":"5","author":"Koshkin","year":"2019","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.clgc.2024.102284_bib0024","first-page":"104","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2024.102284_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4566","article-title":"Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: an open-label phase 1b\/2 study","volume":"41","author":"Sheng","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.102284_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS594","article-title":"Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001)","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.102284_bib0027","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.438","article-title":"Primary analysis from DS8201-A-U105: a phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC)","volume":"40","author":"Galsky","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102284_bib0028","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102284_bib0029","series-title":"FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki for Unresectable or Metastatic HER2-positive Solid Tumors","year":"2024"},{"issue":"3","key":"10.1016\/j.clgc.2024.102284_bib0030","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2024.102284_bib0031","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.clgc.2024.102284_bib0032","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102284_bib0033","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","article-title":"Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer","volume":"76","author":"Wang","year":"2019","journal-title":"Eur Urol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2024.102284_bib0034","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4504","article-title":"Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): final results from the phase 2 Norse study","volume":"41","author":"Siefker-Radtke","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102284_bib0035","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2024.102284_bib0036","article-title":"ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102284_bib0037","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1512942","article-title":"HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy","volume":"8","author":"Triulzi","year":"2018","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.clgc.2024.102284_bib0038","doi-asserted-by":"crossref","first-page":"10371","DOI":"10.1002\/cam4.5769","article-title":"Genetic and immune microenvironment characterization of HER2-positive gastric cancer: their association with response to trastuzumab-based treatment","volume":"12","author":"Kwon","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.clgc.2024.102284_bib0039","first-page":"1","article-title":"Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer","volume":"5","author":"Griguolo","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102284_bib0040","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/cncr.32645","article-title":"Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with checkpoint inhibitors","volume":"126","author":"Khaki","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2024.102284_bib0041","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.euo.2020.12.006","article-title":"A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors","volume":"4","author":"Khaki","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102284_bib0042","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.clgc.2024.102284_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"11","key":"10.1016\/j.clgc.2024.102284_bib0044","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1158\/1541-7786.MCR-10-0168","article-title":"Roles of fibroblast growth factor receptors in carcinogenesis","volume":"8","author":"Haugsten","year":"2010","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2024.102284_bib0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2024.102284_bib0046","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102284_bib0047","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.euf.2020.08.001","article-title":"Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma","volume":"7","author":"Necchi","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"8","key":"10.1016\/j.clgc.2024.102284_bib0048","doi-asserted-by":"crossref","first-page":"e1395","DOI":"10.1002\/onco.13839","article-title":"Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder","volume":"26","author":"Yang","year":"2021","journal-title":"Oncologist"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2024.102284_bib0049","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4511","article-title":"Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: a phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC)","volume":"41","author":"Grivas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2024.102284_bib0050","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/0008-5472.CAN-18-0173","article-title":"Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy","volume":"78","author":"Saito","year":"2018","journal-title":"Cancer Res"},{"issue":"10064","key":"10.1016\/j.clgc.2024.102284_bib0051","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clgc.2024.102284_bib0052","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102284_bib0053","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","article-title":"Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience","volume":"125","author":"Rose","year":"2021","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2024.102284_bib0054","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41591-021-01579-0","article-title":"Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"issue":"7_suppl","key":"10.1016\/j.clgc.2024.102284_bib0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.419","article-title":"Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC)","volume":"37","author":"Santiago-Walker","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102284_bib0056","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102284_bib0057","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1038\/s41598-022-07697-0","article-title":"MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization","volume":"12","author":"Hansen","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.clgc.2024.102284_bib0058","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.euo.2021.10.006","article-title":"Integrative clinical and genomic characterization of MTAP-deficient metastatic urothelial cancer","volume":"6","author":"Alhalabi","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2024.102284_bib0059","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.2622","article-title":"Dual CDKN2A\/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors","volume":"40","author":"Adib","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102284_bib0060","unstructured":"M.D. Anderson Cancer Center. A phase 2 study to evaluate the triplet combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in patients with previously treated advanced or metastatic MTAP deficient urothelial carcinoma [Internet]. clinicaltrials.gov; 2023 May [cited 2023 Jun 14]. Report No.: NCT05335941. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05335941."},{"issue":"7492","key":"10.1016\/j.clgc.2024.102284_bib0061","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Weinstein","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clgc.2024.102284_bib0062","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.clgc.2024.102284_bib0063","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2015.66.3047","article-title":"Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations","volume":"34","author":"Choudhury","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2024.102284_bib0064","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4520","article-title":"RC48-ADC for metastatic urothelial carcinoma with HER2-positive: combined analysis of RC48-C005 and RC48-C009 trials","volume":"40","author":"Sheng","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102284_bib0065","unstructured":"RemeGen Co., Ltd. A Open-Label, Multicenter, Randomised, Controlled phase 3 study of RC48-ADC plus toripalimab versus chemotherapy alone in previously untreated unresectable locally advanced or metastatic urothelial carcinoma with HER2-expressing [Internet]. clinicaltrials.gov; 2022 Aug [cited 2023 Jun 14]. Report No.: NCT05302284. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05302284."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:30:51Z","timestamp":1762551051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1558767324002544"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102284","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2\/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102284"}}